leadf
logo-loader
AIM:SAR FRA:RYH

Sareum Holdings PLC

Receive alerts
Market:
AIM
Market Cap:
£56.37 m
Price
1.73 GBX
Change
1.47%
52 weeks high
3.09
52 weeks low
0.22

In brief

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

Snapshot

  • SRA737 being developed by partner Sierra Oncology
  • Focus on two TYK2/JAK1 pre-clinical programmes
  • These target autoimmune disease, cancer and COVID-19